Across TCGA pan-cancer cohorts, DNAJC9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DNAJC9 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DNAJC9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DNAJC9 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where DNAJC9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	1.000	0.328	.006	21	view →
HNSC	OS	Quartile	All	0.176	0.947	.017	16	view →
LUAD	OS	Tertile	II,III,IV	0.325	0.869	.017	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: DNAJC9 tumor-vs-normal RNA expression · all DNAJC9 data types